Bera A, Das F, Ghosh-Choudhury N, Mariappan MM, Kasinath BS, Ghosh Choudhury G (2017) Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. American journal of physiology Cell physiology 313: C430-C447
Chen YJ, Kong L, Tang ZZ, Zhang YM, Liu Y, Wang TY, Liu YW (2019) Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 111: 1166-1175
Chu HW, Cheng CW, Chou WC, Hu LY, Wang HW, Hsiung CN, Hsu HM, Wu PE, Hou MF, Shen CY, Yu JC (2014) A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. Hum Mol Genet 23: 355-367
Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG (2000) Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. The Journal of experimental medicine 191: 455-462
Fiorentino L, Cavalera M, Mavilio M, Conserva F, Menghini R, Gesualdo L, Federici M (2013) Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta diabetologica 50: 965-969
Guan Y, Nakano D, Li L, Zheng H, Nishiyama A, Tian Y, Zhang L (2021) Protease-Activated Receptor 1 Contributes to Microcirculation Failure and Tubular Damage in Renal Ischemia-Reperfusion Injury in Mice. BioMed research international 2021: 6665714
Guan Y, Nakano D, Zhang Y, Li L, Liu W, Nishida M, Kuwabara T, Morishita A, Hitomi H, Mori K, Mukoyama M, Masaki T, Hirano K, Nishiyama A (2017) A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy. J Pharmacol Sci
Horinouchi Y, Ikeda Y, Fukushima K, Imanishi M, Hamano H, Izawa-Ishizawa Y, Zamami Y, Takechi K, Miyamoto L, Fujino H, Ishizawa K, Tsuchiya K, Tamaki T (2018) Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis. Sci Rep 8: 10858
Kolling M, Kaucsar T, Schauerte C, Hubner A, Dettling A, Park JK, Busch M, Wulff X, Meier M, Scherf K, Bukosza N, Szenasi G, Godo M, Sharma A, Heuser M, Hamar P, Bang C, Haller H, Thum T, Lorenzen JM (2017) Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular therapy : the journal of the American Society of Gene Therapy 25: 165-180
Lok SWY, Yiu WH, Li H, Xue R, Zou Y, Li B, Chan KW, Chan LYY, Leung JCK, Lai KN, Tang SCW (2020) The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. Clinical science 134: 2873-2891
Mitsui S, Oe Y, Sekimoto A, Sato E, Hashizume Y, Yamakage S, Kumakura S, Sato H, Ito S, Takahashi N (2020) Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease. American journal of physiology Renal physiology 318: F1067-F1073
Sakai T, Nambu T, Katoh M, Uehara S, Fukuroda T, Nishikibe M (2009) Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis. Biochem Biophys Res Commun 384: 173-179
Saleiban A, Faxalv L, Claesson K, Jonsson JI, Osman A (2014) miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells. Pigment Cell Melanoma Res 27: 431-441
Tang ZZ, Zhang YM, Zheng T, Huang TT, Ma TF, Liu YW (2020) Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: In vivo and in vitro study. Phytomedicine : international journal of phytotherapy and phytopharmacology 78: 153314
Waasdorp M, de Rooij DM, Florquin S, Duitman J, Spek CA (2019) Protease-activated receptor-1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy. J Cell Mol Med 23: 1268-1279
Waasdorp M, Duitman J, Florquin S, Spek CA (2016) Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice. Sci Rep 6: 33030
Waasdorp M, Duitman J, Florquin S, Spek CA (2018) Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice. Oncotarget 9: 21655-21662
Wang S, Wen X, Han XR, Wang YJ, Shen M, Fan SH, Zhuang J, Zhang ZF, Shan Q, Li MQ, Hu B, Sun CH, Wu DM, Lu J, Zheng YL (2018) Repression of microRNA-382 inhibits glomerular mesangial cell proliferation and extracellular matrix accumulation via FoxO1 in mice with diabetic nephropathy. Cell proliferation 51: e12462
Xu J, Xiang P, Liu L, Sun J, Ye S (2020) Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-beta1 axis. The Journal of pharmacy and pharmacology 72: 1101-1109
Zhao D, Guo J, Liu L, Huang Y (2021) Rosiglitazone attenuates high glucose-induced proliferation, inflammation, oxidative stress and extracellular matrix accumulation in mouse mesangial cells through the Gm26917/miR-185-5p pathway. Endocrine journal 68: 751-762
Zhu X, Shi J, Li H (2018) Liquiritigenin attenuates high glucose-induced mesangial matrix accumulation, oxidative stress, and inflammation by suppression of the NF-kappaB and NLRP3 inflammasome pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 106: 976-982